Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03003 Tolerance and Kinetics
NCT04627155Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Mar 2013
- Primary completion
- May 2013
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of rotigotine in Parkinson's disease (PD) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Plasma drug concentration at Day 21. Started Mar 2013; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04627155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627155.